Safety Management of Incretin-Based Obesity Therapy: Expert Consensus on the Use of Semaglutide and Tirzepatide
Problems of Endocrinology · 2026
DOI: 10.14341/probl13784 ↗At a glance
Journal article in Problems of Endocrinology, 2026. Written by E A Troshina and 8 co-authors. Institution: Endocrinology Research Centre. Major MEDLINE topics: Obesity, Incretins, Glucagon-Like Peptides. Cited 2 times so far (Crossref); 26 references. The full text is freely available in PubMed Central.
Abstract (original language)
On December 3, 2025, a meeting of the expert working group was held in Moscow. The discussion focused on the safety and personalized use of tirzepatide (Tirzetta®) and semaglutide (Velgia® eco) in patients with overweight and obesity. Following the meeting, a consensus position was developed on the optimal use of incretin receptor agonists in real-world clinical practice.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Endocrinology Research Centre.
- Endocrinological Dispensary.
- Russian Medical Academy of Continuing Professional Education.
- St. Petersburg State University.
- Russian University of Medicine.
Cite
APA
Troshina, E. A., Antsiferov, M. B., Ametov, A. S., Bakulin, I. G., Galstyan, G. R., Markova, T. N., Romantsova, T. I., Mazurina, N. V., & Koteshkova, O. M. (2026). Safety Management of Incretin-Based Obesity Therapy: Expert Consensus on the Use of Semaglutide and Tirzepatide. Problems of Endocrinology. https://doi.org/10.14341/probl13784
Vancouver
Troshina EA, Antsiferov MB, Ametov AS, Bakulin IG, Galstyan GR, Markova TN, et al. Safety Management of Incretin-Based Obesity Therapy: Expert Consensus on the Use of Semaglutide and Tirzepatide. Problems of Endocrinology. 2026. doi:10.14341/probl13784
BibTeX
@article{Troshina2026,
author = {Troshina, E A and Antsiferov, M B and Ametov, A S and Bakulin, I G and Galstyan, G R and Markova, T N and Romantsova, T I and Mazurina, N V and Koteshkova, O M},
title = {Safety Management of Incretin-Based Obesity Therapy: Expert Consensus on the Use of Semaglutide and Tirzepatide},
journal = {Problems of Endocrinology},
year = {2026},
doi = {10.14341/probl13784}
}
EUVIMED